Subject: NGCG Updates Shareholders PSID Funded Now for Future Growth MJNA Sub Kannalife Progress

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
NGCG Updates Shareholders PSID Funded Now for Future Growth MJNA Sub Kannalife Progress
Hot Stock to WatchHot Stock to Watch

Company: PositiveID Corporation (OTCQB: PSID)

End of Day:

Price: 0.0278

Change (%): - 0.0002 (0.71)

Volume: 3,512,843
PSID Chart

PositiveID Enters Into Strategic Financing for 2.4 Million Dollars

Proceeds to Be Used to Develop Field-Testable Units of PositiveID’s Firefly Dx Pathogen Detection System for Point-Of-Need Diagnostics

DELRAY BEACH, Fla., Aug. 17, 2015 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today it has entered into definitive agreements with an institutional investor (“Investor”) for an aggregate purchase price of 2,400,000 dollars. PositiveID will use the proceeds to continue the development and testing of its Firefly Dx PCR (polymerase chain reaction) prototype pathogen detection system (“prototype system”) with the goal of producing field-testable units, and for general working capital.

Continue Reading

Top PerformerYesterday's Top Performer

New Generation Consumer Group Inc. (Pink Sheets: NGCG)

End of Day:

Price: 0.0144

Change (%): + 0.0014 (10.77)

Volume: 3,095,983
NGCG Chart

New Generation Consumer Group Announces Open Letter to Shareholders

WHITTIER, CA-(Marketwired - Aug 17, 2015) - New Generation Consumer Group (OTC PINK: NGCG)

Dear Shareholder:

These past several months have been very fast paced, yet exciting. We have come a long way in a short period of time and our momentum is still building. I’m very pleased with where we are, given NGCG is just over eight months old. The team has accomplished a great deal in this short period of time, and I’m impressed with the direction and progress we have made and continue to make.

As I have previously stated, part of our business model is our performance with purpose. We truly see that as our catalyst for our success. We are true innovators and given the many years of experience from our executive team, we have the ability to bring sound knowledge and a distinguished competitive edge that is far more superior than our competitors. We are a true powerhouse in this rapidly growing, and evolving industry.

Continue Reading

SmallCapVoice Clients' News

Medical Marijuana Inc. (Pink Sheets: MJNA)

Medical Marijuana, Inc's Portfolio Investment Company Kannalife Sciences Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents

Milestone Accomplishment to Lead KSI to Further Patents and IP

SAN DIEGO, Aug. 14, 2015 (GLOBE NEWSWIRE) - Medical Marijuana, Inc. portfolio investment company Kannalife Sciences, Inc. has announced the publication of its global WIPO/PCT Patent WO2015/106108A2 - ‘Novel Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy’.

Both hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE) are oxidative stress (OS) related diseases. Neural cells suffer functional or sensory loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress leading to free radical attack on neural cells contributes calamitous role to neuro-degeneration.

Continue Reading

Other Small Cap News

Company: Vivakor Inc. (Pink Sheets: VIVK)

Vivakor Does It Again: 9th Straight Quarter of Positive Financial Results

LAS VEGAS, NV--(Marketwired - August 17, 2015) - Vivakor Inc. (OTC PINK: VIVK) announced GAAP based financial results for the quarter ended June 30, 2015.

Chairman and CEO Matt Nicosia stated, "We are very excited about the fundamental soundness of the Company as evidenced by our ability to recognize nine consecutive quarters of overall positive financial results. Our balance sheet is solid and fundamentally we are exactly where we want to be as a company. The remainder of this year looks good as our precious metals production enables us to increase our total assets for the Company while we continue to contain costs and reduce our liabilities. Last year we announced our intention to move into the alternative energy sector and our effort has resulted in exciting announcements in that area during the past several months. Our first mobile oil extraction unit is being built at this time and Vivakor continues to move in a determined manner as it meets its goals and objectives. All the while staying the course through a practical business plan supported by growth of the overall asset base and valuation accrual for our loyal shareholders."

Continue Reading

Company: Relmada Therapeutics, Inc. (OTCQB: RLMD)

Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist

NEW YORK, Aug. 17, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.

"Initial results from our completed single ascending dose study successfully demonstrated a potentially therapeutic dose range for d-Methadone without the side effects typically observed with racemic methadone in opioid naive subjects or with other NMDA inhibitors, such as ketamine," stated Sergio Traversa, CEO of Relmada Therapeutics. "Assuming successful completion of the multiple ascending dose study, d-Methadone should enter Phase 2 proof of concept clinical development in the first half of 2016."

Continue Reading

Company: Pressure BioSciences, Inc. (OTCQB: PBIO)

Pressure BioSciences, Inc. Reports Second Quarter and Year-to-Date 2015 Financial Results and Provides Business Update

SOUTH EASTON, Mass., Aug. 17, 2015 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three and six-month periods ended June 30, 2015, which included increases in all major revenue categories for the quarter and record total revenue for the half-year period. The Company also provided a business update, which included the sale last week of 1,000,000 shares of restricted common stock at a significant premium to market ($0.46/share) to one of the most recognized and respected portfolio/fund managers in Poland. In return, in lieu of cash, the Company received 601,500 shares of Everest Investments, a publicly-traded company on the Main Market of the Warsaw Stock Exchange.

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Monday, August 17, 2015. To attend this teleconference via telephone: Dial-in: (877) 407-8031 (North America); (201) 689-8031 (International).

Continue Reading

Company: Net Medical Xpress Solutions, Inc. (OTCQB: NMXS)

Net Medical Xpress Announces Q2 Profitability, Positive Cash Flow and Strengthened Balance Sheet on Growing Telemedicine Services

CEO Dick Govatski said, "The results of the second quarter and the first half of 2015 reflect substantial progress of our telemedicine programs and the increasing financial health of our company. This was underscored by the 161% revenue gain in our Specialists segment with strong performances in neurological services, primary care and hospital hardware sales. We are concentrating our efforts to grow this division to offset a temporary slowdown in our radiology and cardiological services where we face increasing competition resulting in pricing pressure.

"Our debt-free balance sheet showed healthy gains in assets and decreases in liabilities. For the first six months we generated $122,000 in cash from operating activities.

Continue Reading

Company: Appalachian Mountain Brewery, Inc. (Pink Sheets: HOPS)

Appalachian Mountain Brewery, Inc. Announces Q2 2015 Revenue Increased by 60%

BOONE, N.C., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Appalachian Mountain Brewery, Inc. (HOPS), announced 2nd Quarter revenue increased significantly and was up 27% to $478,572 compared to 1st Quarter 2015 at $348,844. Revenue increased by 60% to $478,572 for Q2 2015 versus $192,450 for Q2 2014. Net profit increased by 32% in Q2 2015 to $111,852 compared to $76,317 in Q2 2014. AMB’s gross margin remained flat but extremely strong during the 2nd Quarter at 77% compared to the same period 2014.

Effective April 1, 2015, AMB signed a Master Distribution Agreement (MDA) and began implementing our strategic partnership with Craft Brew Alliance (CBA). We are now able to leverage the CBA Wholesale Distribution Network in North Carolina and beyond.

Continue Reading

Market News

By Patti Domm: CNBC

Early movers: PNR, JPM, EL, KKR, T, DIS, WMB, AMZN, CHTR, AAPL & more

Check out which companies are making headlines before the bell:

Pentair - The maker of thermal management products is acquiring privately held electrical products maker Erico Global for $1.8 billion in cash. Nelson Peltz's Trian, which took a stake in Pentair earlier this year, had been pushing for the company to be involved in industry consolidation deals.

JPMorgan Chase - The bank's stock was upgraded to "outperform" from "market perform" at KBW, saying JPM is undervalued compared to its peer group given its prospects for solid profitability.

Estee Lauder - The cosmetics maker reported quarterly profit of 40 cents per share, 6 cents above estimates, though revenue was slightly below forecasts. The company said it is pleased with its performance despite "macroeconomic headwinds and challenges."

Continue Reading

By Fred Imbert :

Dow falls 100 points amid oil, manufacturing data; Fed eyed

U.S. stocks kicked off the week lower on Monday, as investors digested weak manufacturing data and falling oil prices while eyeing the release of the Federal Reserve's minutes.

"You can't ignore that the New York manufacturing numbers came in so weak," said Mark Luschini, chief investment strategist at Janney Montgomery Scott.

The New York Fed said that manufacturing activity for the state fell from 3.86 in July to -14.92 in August, its lowest since April 2009.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks